SCHEMBL3754553

SCHEMBL3754553

O=C(O)c1cc(Cc2ccc(Cl)cc2)cn1Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
KDM4E B2RXH2 2/20 0.59
MAPK1 P28482 2/20 0.59
LMNA P02545 2/20 0.59
POLB P06746 1/20 0.59
MAPT P10636 1/20 0.59
CCR2 P41597 3/20 0.58
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MDM2 Q00987 1/20 0.44
AMY1A P0DUB6 1/20 0.42
TSHR P16473 1/20 0.42
CXCR3 P49682 1/20 0.41
THRA P10827 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661539 0.80 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2KDM4EMAPK1LMNA
SCHEMBL3756292 0.80 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2KDM4EMAPK1LMNA
SCHEMBL2662256 0.79 MAPT (0.46) ALDH1A1SMN1; SMN2KDM4ELMNAMAPT
SCHEMBL2662339 0.78 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KDM4EMAPK1LMNA
SCHEMBL27776171 0.76 CCR2 (0.50) ALDH1A1SMN1; SMN2KDM4EMAPK1LMNA
SCHEMBL3748510 0.75 CCR9 (0.48) ALDH1A1SMN1; SMN2KDM4EMAPTCCR2
SCHEMBL15103999 0.72 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2KDM4EMAPK1LMNA
SCHEMBL8186880 0.72 TP53 (0.61) ALDH1A1SMN1; SMN2KDM4EMAPK1LMNA
SCHEMBL987905 0.71 ADRA1D (0.54) ALDH1A1SMN1; SMN2MAPTCCR2
SCHEMBL3760535 0.70 PTGDR2 (0.43) ALDH1A1SMN1; SMN2MAPTCCR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP claimed
US-8299115-B2 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2012-10-30 US claimed
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-11-18 US claimed
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP disclosed
US-8299115-B2 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2012-10-30 US disclosed
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION GCK, PCK1, GCKR ALDH1A1 1904/4885SMN1; SMN2 2730/4885KDM4E 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.